Less Ads, More Data, More Tools Register for FREE

Pin to quick picksOxford Biomedica Regulatory News (OXB)

Share Price Information for Oxford Biomedica (OXB)

Share Price is delayed by 15 minutes
Get Live Data
625.00    -5.00 (-0.79%)
Bid:
618.00
Ask:
621.00
Spread: 3.00 (0.485%)
Market Cap: £756.31m
OXB Live PriceLast checked at - London Stock Exchange

Intraday Oxford Biomedica Share Chart

Director/PDMR Shareholding

5 May 2016 09:22

RNS Number : 3454X
Oxford Biomedica PLC
05 May 2016
 

Notification of Transactions of Directors/Persons Discharging Managerial Responsibility and Connected Persons

 

1

Issuer

Oxford BioMedica PLC

2

Reason for notification

Notification relates to DTR 3.1.2R

3

Name of PDMR

Martin Diggle

4

Connected person

Notification relates to following connected persons:

Vulpes Life Sciences Fund

5

Notification in respect of

Notification in respect of holdings of persons in 4 above

6

Description of shares

Oxford BioMedica PLC ordinary shares of 1p each

7

Name of registered shareholders and number of shares

Vulpes Life Sciences Fund - 475,705,311 shares

8

Nature of transaction

Acquisition

9

Number of shares acquired

 

Vulpes Life Sciences Fund - 44,689 shares

 

10

Percentage of issued class acquired

Vulpes Life Sciences Fund - 0.01%

 

11

Shares disposed

N/A

 

12

Percentage of issued class disposed

N/A

 

13/14

Price per share of transactions, and date

Vulpes Life Sciences Fund

44,689 shares @ £0.057 , 04 May 2016

 

15

Total holding following notification and total percentage holding following notification

Vulpes Life Sciences Fund - 475,750,000 shares

17.60%

16

Date issuer informed

05 May 2016

23

Any additional information

None

24

Contact name and telephone number

T. Watts, Chief Financial Officer

Oxford BioMedica

+44 (0)1865 783000

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
DSHGIGDUGDGBGLU
Date   Source Headline
30th Jun 201710:38 amRNSRefinancing of Debt Facility
23rd Jun 201710:12 amRNSDirector Dealings / Market Share Purchase
14th Jun 20173:00 pmRNSFindings from Phase II JULIET Study
7th Jun 20177:00 amRNSOXB notes FDA Advisory Committee to review CTL019
2nd Jun 20177:00 amRNSOXB to Present at Jefferies Healthcare Conference
1st Jun 201712:22 pmRNSTotal Voting Rights
24th May 20171:55 pmRNSDirector/PDMR Shareholding
23rd May 20172:03 pmRNSResult of AGM
4th May 20178:46 amRNSTotal Voting Rights
28th Apr 20177:00 amRNSAnnual Report and Accounts & AGM Notification
24th Apr 201710:17 amRNSDirector/PDMR Shareholding
4th Apr 20177:00 amRNSHolding(s) in Company
3rd Apr 20179:11 amRNSTotal Voting Rights
31st Mar 20177:15 amRNSHardman: Delivering commercial gene-therapy vector
30th Mar 20177:02 amRNSBLA filing for CTL019
27th Mar 201710:44 amRNSPublication in the Journal Nature Communications
23rd Mar 20171:47 pmRNSDirector Dealings
22nd Mar 20177:00 amRNSHolding(s) in Company
16th Mar 20177:00 amRNSPRELIMINARY RESULTS FOR THE YEAR ENDED 31 DEC 2016
10th Mar 20177:00 amRNSNotice of Preliminary Results
1st Mar 201710:24 amRNSTotal Voting Rights
28th Feb 20177:00 amRNSAppointment of New Chief Financial Officer
24th Feb 20179:36 amRNSDirector Dealings
24th Feb 20177:00 amRNSResults of TroVax® in Advanced Colorectal Cancer
1st Feb 201710:09 amRNSTotal Voting Rights
25th Jan 20179:02 amRNSDirector/PDMR Shareholding
24th Jan 20174:34 pmRNSDirector Dealings / Market Share Purchase
24th Jan 20179:31 amRNSDirector/PDMR Shareholding
23rd Jan 20179:57 amRNSDirector/PDMR Shareholding
3rd Jan 20179:30 amRNSBlock Listing Return
3rd Jan 20179:28 amRNSTotal Voting Rights
20th Dec 20168:57 amRNSDirector/PDMR Shareholding
12th Dec 201610:52 amRNSBlock listing application
6th Dec 20169:15 amRNSDirector/PDMR Shareholding
5th Dec 201610:25 amRNSFindings Reported by Novartis on CTL-019 at ASH
5th Dec 20169:43 amRNSDirector/PDMR Shareholding
1st Dec 20169:27 amRNSTotal Voting Rights
29th Nov 20167:00 amRNSStrategic Alliance with Orchard Therapeutics
28th Nov 201610:06 amRNSDirector/PDMR Shareholding
8th Nov 20166:28 pmRNSGrant of options (Replacement)
8th Nov 20166:13 pmRNSGrant of options
1st Nov 201610:21 amRNSTotal Voting Rights
25th Oct 20164:40 pmRNSDirector/PDMR Shareholding
10th Oct 20167:21 amRNSPublication of RetinoStat® (OXB-201) Phase I study
6th Oct 20169:24 amRNSHolding(s) in Company
5th Oct 201610:17 amRNSHolding(s) in Company
4th Oct 201611:57 amRNSHolding(s) in Company
4th Oct 20168:16 amRNSAdmission to Trading and Total Voting Rights
29th Sep 201612:27 pmRNSResult of General Meeting and Directors Dealing
26th Sep 201611:00 amRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.